Matthew E Wiisanen, MD

Director of Structural Heart Disease
Erlanger Heart and Lung Institute
Assistant Professor of Medicine
UT Erlanger Cardiology

Tel: n/a


  • None, University of Kentucky - Lexington, KY, Interventional Cardiology
  • None, University of Kentucky - Lexington, KY, Cardiovascular Disease
  • None, Mayo Clinic - Rochester, MN, Internal Medicine
  • M.D., University of Minnesota - Minneapolis, MN, Medicine
  • B.A., St. John's University - Collegeville, MN, Natural Science

Research Interest/Specialty

-Structural Heart Disease therapies -Cardiogenic shock support -Coronary artery disease revascularization -Pulmonary embolism -Endocarditis treatments


  1. Drofa, A, Kouznetsov, E, Tomek, S, Wiisanen, M, Manchak, M, Lindley, T, Mitchell, S, Hui, F, Breker, D. Successful Endovascular Management of Massive Pansinus Thrombosis: Case Report and Review of Literature. Pediatr Neurosurg, 51 (6), 318-324, 2016.
  2. Wiisanen, ME, Moliterno, DJ. Platelet protease-activated receptor antagonism in cardiovascular medicine. Coron Artery Dis, 23 (6), 375-9, 2012.
  3. Lea, B, Bailey, AL, Wiisanen, ME, Attili, A, Rajagopalan, N. Left ventricular noncompaction presenting as peripartum cardiomyopathy. Int J Cardiol, 154 (3), e65-6, 2012.
  4. Elayi, CS, Allen, CL, Leung, S, Lusher, S, Morales, GX, Wiisanen, M, Aikat, S, Kakavand, B, Shah, JS, Moliterno, DJ, Gurley, JC. Inside-out access: a new method of lead placement for patients with central venous occlusions. Heart Rhythm, 8 (6), 851-7, 2011.
  5. Wiisanen, ME, Abdel-Latif, A, Mukherjee, D, Ziada, KM. Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis. JACC Cardiovasc Interv, 3 (12), 1262-73, 2010.
  6. Wiisanen, ME, Moliterno, DJ. The use of single versus dual antiplatelet therapy beyond 1 year following drug-eluting stent implantation. Curr Cardiol Rep, 12 (5), 357-60, 2010.
  7. Shaikh, A, Wiisanen, ME, Gunderson, HD, Leung, N. Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab. Ann Pharmacother, 43 (7), 1370-3, 2009.